Released May 8, 2024, after the close
10-Q filed May 8, 2024, 38 days after period end · 0000950170-24-055680
Q1 2024 · 10-Q
Revenue$5.79M$5.79M — vs Q1 2023−19.2% vs Q4 2023
Net Income-$9.08M-$9.08M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$1.66-$1.66 N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$10,729,000N/M
Operating Cash Flow-$18,364,000N/M
Free Cash Flowderived-$18,378,000N/M
Margins · derived
Operating margin-185.5%
Net margin-156.9%
What the release said
The release
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $5.79M | $0.00 | — | — |
| Net Income | -$9.08M | -$18.95M | -$23.09M | -$27.20M |
| EPS Diluted | -$1.66 | -$4.46 | -$0.48 | -$0.69 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR